Dosimetric predictors of radiation esophagitis in patients treated for non-small-cell lung cancer with carboplatin/paclitaxel/radiotherapy

International Journal of Radiation Oncology Biology Physics

Volumn 51, Issue 2, 2001, Pages 291-295

  Hirota, Saeko ^a   Tsujino, Kayoko ^a   Endo, Masahiro ^a   Kotani, Yoshikazu ^a   Satouchi, Miyako ^a   Kado, Tetsuji ^a   Hishikawa, Yoshio ^b   Obayashi, Kayoko ^a   Takada, Yoshiki ^a   Kono, Michio ^a   Abe, Mitsuyuki ^b  

^a HYOGO MEDICAL CENTER FOR ADULTS   (Japan)

^b HYOGO ION BEAM MEDICAL CENTER   (Japan)

Author keywords

Dosimetric predictor; Non small cell lung cancer; Paclitaxel; Radiation esophagitis; Superposition algorithm

Indexed keywords

ALGORITHMS; BIOLOGICAL ORGANS; DOSIMETRY; PULMONARY DISEASES; STATISTICAL METHODS; TUMORS;

CARBOPLATIN;

RADIOTHERAPY;

CARBOPLATIN; PACLITAXEL;

ADULT; AGED; ALGORITHM; ARTICLE; CLINICAL ARTICLE; DOSIMETRY; ESOPHAGITIS; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM PERMISSIBLE DOSE; PRIORITY JOURNAL; RADIATION INJURY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; ESOPHAGITIS; ESOPHAGOSCOPY; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; RADIATION INJURIES; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL;

EID: 0035479074     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(01)01648-0     Document Type: Article

References (15)

1. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer
2. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer
3. Preliminary advanced results of a phase III trial of regionally unresectable non-small cell lung cancer
4. Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small cell lung cancer
5. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small cell lung cancer; A randomized study
6. Esophagitis in combined modality therapy for locally advanced non-small cell lung cancer
7. Endoscopic findings of radiation esophagitis in concurrent chemoradiotherapy for intrathoracic malignancies
8. True three-dimensional dose computations for megavoltage X-ray therapy; A role for the superposition principle
9. Clinical and dosimetric predictors of radiation-induced esophageal toxicity
10. Predictors of severe esophagitis include use of concurrent chemotherapy, but not the length of irradiated esophagus; A multivariate analysis of patients with lung cancer treated with nonoperative therapy
11. Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung
12. Twice-daily compared with once-daily thoracic radiotherapy in limitied small-cell lung cancer treated concurrently with cisplatin and etoposide
13. Toxicity of combined radiation and chemotherapy in non-small cell lung cancer
14. Induction paclitaxel and carboplatin followed by concurrent chemoradiotherapy in patients with unresectable, locally advanced non-small cell lung carcinoma; Report of Fox Chase Cancer Center Study 94-001